Lectures

  • Patients with Elevated GCK Have More SST Cells. 77st Scientific Sessions of the American Diabetes Association. June 2017. San Diego, USA.
  • Patients with Overactivated GCK Have More SST Cells and… ӦRESUND ISLET STUDY GROUP. Workshop on “Islet Cell Plasticity” . Faculty Club, Panum Institute. June 2017. Copenhagen, Denmark.
  • Glucokinase gene mutations and Diabetes. New Horizons on Diabetes Therapy. Universidade Estadual de Campinas – UNICAMP, 18 de Maio de 2016. Brasil
  • Keynote Lecture. From Monogenic Beta-Cell Defects Straight to Pharmacogenetics. 1st PHARMACOGENOMICS İSTANBUL SUMMIT, Increasing the Safety and Effectiveness of Personalized Therapy for Metabolic Disorders. European Society of Pharmacogenomics and Personalised Therapy (ESPT). 27-28 November, 2015. İstanbul, Turkey.
  • Activating glucokinase gene mutations: From human model to cell therapy? Danish Diabetes Academy. Panum Institute. Copenhagen. Denmark. October 2013.
  • Highly efficient human islets due to activating glucokinase gene mutations: lessons from human models. EASD Islet Study Group – Rostock, Alemania October 2012.
  • Glucokinase Gene Activation and Highly Efficient Human Islets: Lessons from Human Models. 72st Scientific Sessions of the American Diabetes Association. June 2012. Filadelfia, USA.
  • Monogenic Diabetes, genetic analysis. When should be done? 54 Meeting of the Spanish Society of Endocrinology and Nutrition. Mayo 2012, Oviedo, Spain.
  • Monogenic Diabetes, how to identify and treat them. VI Reunión de Diabetes y Obesidad, SEMI, Enero 2012, Zaragoza, Spain.
  • Replication of Beta cell Proliferation in Islets Containing the Naturally Occurring Activating Glucokinase Gene Mutation V91L. Implications for Cell Therapy. Workshop: Programming Beta Cell Development, Impairment and Regeneration 23-26 October 2011, LO-skolen, Helsingør, Denmark
  • Human Islets Proliferation and Glucokinase Mutations “The Genetics of Diabetes in the Post-Genome Wide Association Era” 3rd Biannual Congress of EASD-SGGD. September 30th – October 2nd, 2011. Smolenice Castle, Bratislava, Slovakia
  • Impact of naturally occurring severe activating glucokinase mutation gene in human islets. 21th EASD- Islets Study Group. May, 8 – 11, 2011. Natal, Rio Grande do Norte, Brazil
  • Glucokinase and Highly Efficient Islets; The paradox of how hypoglycaemia can help hyperglycemia. 2 Ulusal Hücresel Tedavi ve Rejenerative Tip Kongresi. Izmir, Turkey 11-13 Febrero 2011
  • Large Islets, Beta-Cell Proliferation and a Glucokinase Mutation. The paradox of how hypoglycaemia can help hyperglycemia. “Cell Transplant Center Research Conference” Diabetes Research Institute (DRI). Univeristy of Miami Leonard M. Miller School of Medicine June 30, 2010.Miami, FL. USA
  • Large Islets, Beta-Cell Proliferation and a Glucokinase Mutation. Instituto de Biomedicina de Valencia (CSIC). Abril 2010.Valencia, Spain.
  • Glucokinase Hypoglycemia. “Fundamentos Moleculares de la Medicina” Real Academia Nacional de Medicina. 6-7 Mayo, 2009 Madrid, Spain.
  • Glucokinase and hypoglycemia. Second Meeting of the EASD Study Group on Genetics of Diabetes (EASD-SGGD).Bergen, Norway. April 2009.
  • Monogenic Diabetes. XXIII Curso de Endocrinología para Postgrado 2008. Sociedad Española de Endocrinología y Nutrición. 9-11 Marzo 2008. Madrid, Spain.
  • Clinical and pharmacological spectrum of GCK activating mutation. First Meeting of the EASD Study Group on Genetics of Diabetes (EASD-SGGD)4 y 5 de Octubre 2007. Málaga, Spain.
  • Monogenic Pancreatic b-cell Disease. International Symposium “Bioengineering of Pancreatic Islet”  CABIMER 11th-12th January 2007 Sevilla, Spain.
  • Monogenic Diabetes and Pharmacogenetics. II Official Joint Meeting ADA – SED Septiembre de 2006. Madrid, Spain.
  • “Clinical and molecular aspects of the Familial Hyperinsulinism due to Glucokinase” Activating Mutations. International symposium: “Congenital hyperinsulinism and related disorders of insulin secretion:  Clinical, biochemical and genetic advances”. Philadelphia, USA. June 15-16, 2006.
  • Keynote Lecture. Activating Mutations in glucokinase gene and glucose homeostasis. XVIII Scientific Meeting of the Spanish Diabetes Society. Febrero de 2006. Madrid, Spain.
  • “Is glucokinase a target only for treatment of type 2 diabetes?” some considerations.  European Islets Study Group (EASD). Noviembre 11 – 12, 2005. Alicante, Spain.
  • “Glucokinase disease. clinical diagnosis, functional studies and something else”. University Medical Centre of Geneva, Switzerland 9 de mayo 2005. Geneva, Switzerland.
  • “Heterogenous hyperinsulinemic phenotype of glucokinase disease.” Managing Beta-cell Diseases in the Postgenomic Era:  First Meeting of the European Group for the Study of Monogenic Diabetes. 21-22 Octubre del 2004. Málaga, Spain.
  • “Glucokinase, anithing else?. Should “MODY” stand for maturity onset diabetes of the young?”.  Diabetes and Vascular Medicine.
  • Molecular Genetics Laboratory, Royal Devon& Exeter Hospital, Exeter, England. 28 de Abril de 2004. Exeter, England.
  • “Glucokinase disease. should “mody” stand for maturity onset diabetes of the young?”. Children’s Hospital of Pittsburgh, General Clinical Research Center and University of Pittsburgh School of Medicine. 14 Noviembre 2003. Pittsburg. Pennsylvania, USA.
  • Keynote Lecture. “Diabetes tipo 2 y mody en el adolescente”.1ª Jornadas de Endocrinología Pediátrica del Hospital Dona Estefanía. Título: Mayo 2003, Lisboa, Portugal.
  • “Molecular Bases of Diabetes MODY”. XVI Scientific Meeting of the Spanish Diabetes Society 2 – 5 Marzo, 2002.  Cádiz, Spain
  • «Glucokinase, from basics to therapeutics. Why?”. Scientific Sessions on Diabetes. Novo Nordisk. 24 Septiembre, 2001. Copenhagen, Denmark.

Professional Societies

  • Honorary President of the EASD-European Study Group of Genetics of Diabetes (EASD-SGGD).
  • Founder of the EASD-European Study Group of Genetics of Diabetes (EASD-SGGD).
  • President of the Spanish Study Group of Monogenic Diabetes. Spanish Diabetes Society.
  • Founder of the Spanish Study Group of Monogenic Diabetes. Spanish Diabetes Society.
  • Member of the Danish Diabetes Academy
  • Spanish Genetic Society
  • Spanish Diabetes Society
  • Spanish Endocrinology Society.
  • Member of the European Association for the Study of Diabetes.
  • Member of the European Society of Human Genetics.
  • Member of the American Diabetes Association.
  • Member of the Spanish Society of Authors

Honors

  • Keynote Lecture. From Monogenic Beta-Cell Defects Straight to Pharmacogenetics. 1st PHARMACOGENOMICS İSTANBUL SUMMIT, Increasing the Safety and Effectiveness of Personalized Therapy for Metabolic Disorders. European Society of Pharmacogenomics and Personalised Therapy (ESPT). 27-28 November, 2015. İstanbul, Turkey.
  • Keynote Lecture. Activating Mutations in glucokinase gene and glucose homeostasis. XVIII Scientific Meeting of the Spanish Diabetes Society. 2006. Madrid, Spain.
  • Keynote Lecture. Glucokinase and Highly Efficient Islets; The paradox of how hypoglycaemia can help hyperglycemia. 2 Ulusal Hücresel Tedavi ve Rejenerative Tip Kongresi. Izmir, Turkey 2011.
  • Keynote Lecture. Glucokinase Hypoglycemia. “Fundamentos Moleculares de la Medicina” Spanish Royal National Academy of Medicine. 2009 Madrid, Spain.